Transplantation Infection
4
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
2
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
SandozAustria - Kundl
3 programs1
2
EverolimusPhase 4
EverolimusPhase 4
Everolimus 0.25 and 0.75 mg tabletsPhase 3
ADMA BiologicsNJ - Ramsey
1 program1
Hepatitis C Immune Globulin Intravenous (Human)Phase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
ADMA BiologicsHepatitis C Immune Globulin Intravenous (Human)
Colorado Therapeuticsimmunization app
Clinical Trials (2)
Total enrollment: 52 patients across 2 trials
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
Start: May 2007Est. completion: Feb 20097 patients
Phase 2Terminated
Improving Immunization Rates in Transplant Candidates Through the Use of a Health Information Technology Tool
Start: Jan 2022Est. completion: Aug 202445 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.